JP2016513697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513697A5 JP2016513697A5 JP2016502439A JP2016502439A JP2016513697A5 JP 2016513697 A5 JP2016513697 A5 JP 2016513697A5 JP 2016502439 A JP2016502439 A JP 2016502439A JP 2016502439 A JP2016502439 A JP 2016502439A JP 2016513697 A5 JP2016513697 A5 JP 2016513697A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- amino acid
- variant
- positions
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 108010054218 Factor VIII Proteins 0.000 claims 11
- 102000001690 Factor VIII Human genes 0.000 claims 11
- 229960000301 factor viii Drugs 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 108090000190 Thrombin Proteins 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 229960004072 thrombin Drugs 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789112P | 2013-03-15 | 2013-03-15 | |
| US61/789,112 | 2013-03-15 | ||
| PCT/US2014/027443 WO2014152530A1 (en) | 2013-03-15 | 2014-03-14 | Variant factor viii polypeptides and methods of their production and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513697A JP2016513697A (ja) | 2016-05-16 |
| JP2016513697A5 true JP2016513697A5 (enExample) | 2017-04-06 |
| JP6523244B2 JP6523244B2 (ja) | 2019-05-29 |
Family
ID=51581235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502439A Expired - Fee Related JP6523244B2 (ja) | 2013-03-15 | 2014-03-14 | 変異体第ｖｉｉｉ因子ポリペプチドならびにそれらの製造方法および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9914764B2 (enExample) |
| EP (2) | EP2988758B1 (enExample) |
| JP (1) | JP6523244B2 (enExample) |
| CN (1) | CN105209488A (enExample) |
| CA (1) | CA2906602A1 (enExample) |
| ES (1) | ES2680942T3 (enExample) |
| HK (1) | HK1213274A1 (enExample) |
| WO (1) | WO2014152530A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019197524A1 (en) * | 2018-04-12 | 2019-10-17 | Biotest Ag | De-immunized factor viii molecule and pharmaceutical compositions comprising the same |
| WO2021113800A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| US20250250322A1 (en) * | 2022-04-25 | 2025-08-07 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5004803A (en) * | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| US8183344B2 (en) | 1996-04-24 | 2012-05-22 | University Of Michigan | Inactivation resistant factor VIII |
| DE69735421T2 (de) | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| JP2005538694A (ja) * | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾されたｖｉｉｉ因子 |
| WO2006027111A1 (en) * | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
| JP2008534559A (ja) * | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固ｆｖｉｉｉ類似体 |
| AU2006233638A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation Factor VIII with enhanced stability and its derivates |
| US20080070251A1 (en) * | 2006-06-30 | 2008-03-20 | Kaufman Randal J | Method of Producing Factor VIII Proteins by Recombinant Methods |
| US20120028900A1 (en) | 2006-06-30 | 2012-02-02 | Kaufman Randal J | Method of producing factor viii proteins by recombinant methods |
| US20090203077A1 (en) * | 2006-06-30 | 2009-08-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| CA2703948A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| US8637448B2 (en) * | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
-
2014
- 2014-03-14 ES ES14770221.1T patent/ES2680942T3/es active Active
- 2014-03-14 US US14/773,702 patent/US9914764B2/en not_active Expired - Fee Related
- 2014-03-14 HK HK16101335.4A patent/HK1213274A1/zh unknown
- 2014-03-14 EP EP14770221.1A patent/EP2988758B1/en not_active Not-in-force
- 2014-03-14 EP EP18159477.1A patent/EP3427744A1/en not_active Withdrawn
- 2014-03-14 CA CA2906602A patent/CA2906602A1/en not_active Abandoned
- 2014-03-14 JP JP2016502439A patent/JP6523244B2/ja not_active Expired - Fee Related
- 2014-03-14 CN CN201480027204.2A patent/CN105209488A/zh active Pending
- 2014-03-14 WO PCT/US2014/027443 patent/WO2014152530A1/en not_active Ceased
-
2018
- 2018-01-23 US US15/878,012 patent/US10266583B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530504A5 (enExample) | ||
| JP2011087580A5 (enExample) | ||
| JP2012102105A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2012511545A5 (enExample) | ||
| JP2015214545A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2009540801A5 (enExample) | ||
| JP2015164424A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2014502156A5 (enExample) | ||
| JP2015521206A5 (enExample) | ||
| JP2014529399A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| JP2017536124A5 (enExample) | ||
| JP2018537089A5 (enExample) | ||
| HRP20241627T1 (hr) | Pneumolizinski mutanti i postupci za njihovu uporabu | |
| JP2020513810A5 (enExample) | ||
| JP2016511221A5 (enExample) | ||
| JP2016513697A5 (enExample) | ||
| JP2013531491A5 (enExample) | ||
| HRP20161009T1 (hr) | Modificirani omci kao inhibitor komplementa |